INVENTIVA: Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
Inventiva (Euronext Paris and Nasdaq: IVA) said it completed its EIB warrant restructuring, issuing 15.7 million new EIB warrants to the European Investment Bank and cancelling remaining legacy EIB warrants not repurchased. New warrants are priced and exercisable at €0.01, expire Jan. 4, 2036, and would equal about 6.5% of current share capital if exercised.
How this was made
The 30-second read
Why it matters
By replacing legacy EIB Tranche B warrants not repurchased with a new warrant instrument lacking specific anti-dilution protection and a put option, Inventiva reduces contractual complexity and potential future dilution uncertainty.
Market read
Traders can update capital-structure models for potential dilution: 15.7M new warrants at €0.01 exercise price, exercisable from Aug 30, 2026 to Jan 4, 2036, with legacy warrant features removed.
What to watch
The article does not quantify incremental cash proceeds from this specific step, so traders may overestimate immediate balance-sheet impact versus the broader June 2 refinancing.
Background
Inventiva previously announced a comprehensive EIB refinancing (June 2, 2026) and is now completing the final step via issuance of new EIB warrants and cancellation of remaining legacy EIB warrants.
Ticker impact
Inventiva completed its EIB warrant restructuring, issuing 15.7M new warrants at €0.01 and canceling remaining legacy EIB warrants.
Near-term impact likely modest, with focus shifting to broader refinancing and ongoing lanifibranor development milestones.
This is a capital-structure mechanics update with defined warrant terms (exercise price, maturity, cancellation), but no new cash amount or clinical milestone is disclosed in this text.
Market effects
Biopharma financing structures may be read across for how EIB warrant terms can be simplified to reduce dilution uncertainty.
Primarily affects European small/mid-cap biotech sentiment tied to EIB-backed refinancing.
Limited beyond cross-border biotech financing optics and capital-structure risk perception.
Counterpoint
Simplifying warrant terms does not eliminate dilution risk; if warrants are exercised, equity supply increases and could cap upside.
Key entities
- issuerInventiva
Clinical-stage biopharmaceutical company focused on lanifibranor for MASH; subject of the EIB warrant restructuring announcement.
- counterpartyEuropean Investment Bank (EIB)
Holds legacy EIB warrants and receives new EIB warrants as part of the restructuring; surrenders remaining legacy warrants for cancellation.
